Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy

Sleep Medicine

Volumn 12, Issue 10, 2011, Pages 941-946

  Baier, P C ^a   Hallschmid, M ^b   Seeck Hirschner, M ^a   Weinhold, S L ^a   Burkert, S ^a   Diessner, N ^a   Goder R ^a   Aldenhoff, J B ^a   Hinze Selch, D ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Hypocretin 1; Intranasal administration; Narcolepsy with cataplexy; Nocturnal sleep; Orexin A; REM sleep stability

Indexed keywords

FENETYLLINE; FLUOXETINE; IMIPRAMINE; METHYLPHENIDATE; MODAFINIL; OREXIN A; OXYBATE SODIUM; PLACEBO; VILOXAZINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CATAPLEXY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ELECTROOCULOGRAPHY; EVENING DOSAGE; FEMALE; HUMAN; MALE; NARCOLEPSY; PILOT STUDY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SLEEP TIME; SLEEP WAKING CYCLE; TREATMENT OUTCOME; WAKEFULNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED;

ADMINISTRATION, INTRANASAL; ADULT; AGED; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NARCOLEPSY; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; PILOT PROJECTS; POLYSOMNOGRAPHY; SLEEP, REM; TREATMENT OUTCOME; WAKEFULNESS; YOUNG ADULT;

EID: 84859899795     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2011.06.015     Document Type: Article

References (40)

1. Tsujino N., Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev 2009, 61:162-176.
2. Fontana A., Gast H., Reith W., Recher M., Birchler T., Bassetti C.L. Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss?. Brain 2010, 133:1300-1311.
3. Hallmayer J., Faraco J., Lin L., Hesselson S., Winkelmann J., Kawashima M., et al. Narcolepsy is strongly associated with the TCR alpha locus. Nat Genet 2009, 41:708-711.
4. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
5. Thannickal T.C., Nienhuis R., Siegel J.M. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 2009, 32:993-998.
6. Mignot E., Lammers G.J., Ripley B., Okun M., Nevsimalova S., Overeem S., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553-1562.
7. Knudsen S., Gammeltoft S., Jennum P.J. Rapid eye movement sleep behaviour disorder in patients with narcolepsy is associated with hypocretin-1 deficiency. Brain 2010, 133:568-579.
8. Knudsen S., Jennum P.J., Alving J., Sheikh S.P., Gammeltoft S. Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population. Sleep 2010, 33:169-176.
9. Hara J., Beuckmann C.T., Nambu T., Willie J.T., Chemelli R.M., Sinton C.M., et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001, 30:345-354.
10. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., et al. Narcolepsy in orexin knockout mice. molecular genetics of sleep regulation. Cell 1999, 98:437-451.
11. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
12. Willie J.T., Chemelli R.M., Sinton C.M., Tokita S., Williams S.C., Kisanuki Y.Y., et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice. molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003, 38:715-730.
13. Hagan J.J., Leslie R.A., Patel S., Evans M.L., Wattam T.A., Holmes S., et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA 1999, 96:10911-10916.
14. Bourgin P., Huitron-Resendiz S., Spier A.D., Fabre V., Morte B., Criado J.R., et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 2000, 20:7760-7765.
15. Piper D.C., Upton N., Smith M.I., Hunter A.J. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000, 12:726-730.
16. Xi M.C., Morales F.R., Chase M.H. Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. Brain Res 2001, 901:259-264.
17. Mieda M., Willie J.T., Hara J., Sinton C.M., Sakurai T., Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA 2004, 101:4649-4654.
18. Fujiki N., Yoshida Y., Ripley B., Mignot E., Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003, 26:953-959.
19. John J., Wu M.F., Siegel J.M. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online 2000, 3:23-28.
20. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci 2009, 98:2501-2515.
21. Deadwyler S.A., Porrino L., Siegel J.M., Hampson R.E. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007, 27:14239-14247.
22. Baier P.C., Weinhold S.L., Huth V., Gottwald B., Ferstl R., Hinze-Selch D. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1). Brain 2008, 131:2734-2741.
23. Buskova J., Klaschka J., Sonka K., Nevsimalova S. Olfactory dysfunction in narcolepsy with and without cataplexy. Sleep Med 2010, 11:558-561.
24. Bayard S., Plazzi G., Poli F., Serra L., Ferri R., Dauvilliers Y. Olfactory dysfunction in narcolepsy with cataplexy. Sleep Med 2010, 11:876-881.
25. Stiasny-Kolster K., Clever S.C., Moller J.C., Oertel W.H., Mayer G. Olfactory dysfunction in patients with narcolepsy with and without REM sleep behaviour disorder. Brain 2007, 130:442-449.
26. Stiasny-Kolster K., Doerr Y., Moller J.C., Hoffken H., Behr T.M., Oertel W.H., et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005, 128:126-137.
27. Billiard M. Diagnosis of narcolepsy and idiopathic hypersomnia. An update based on the International classification of sleep disorders, 2nd edition. Sleep Med Rev 2007, 11:377-388.
28. Hublin C., Kaprio J., Partinen M., Koskenvuo M., Heikkila K. The Ullanlinna Narcolepsy Scale: validation of a measure of symptoms in the narcoleptic syndrome. J Sleep Res 1994, 3:52-59.
29. Hallschmid M., Gais S., Meinert S., Born J. NPY attenuates positive cortical DC-potential shift upon food intake in man. Psychoneuroendocrinology 2003, 28:529-539.
30. Hallschmid M., Benedict C., Schultes B., Fehm H.L., Born J., Kern W. Intranasal insulin reduces body fat in men but not in women. Diabetes 2004, 53:3024-3029.
31. Hallschmid M., Smolnik R., McGregor G., Born J., Fehm H.L. Overweight humans are resistant to the weight-reducing effects of melanocortin 4-10. J Clin Endocrinol Metab 2006, 91:522-525.
32. Hanson L.R., Martinez P.M., Taheri S., Kamsheh L., Mignot E., Frey W.H. Intranasal administration of hypocretin 1 (orexin A) bypasses the blood-brain barrier and targets the brain: a new strategy for the treatment of narcolepsy. Drug Delivery Technics 2004, 4:1-10.
33. Benedict C., Brede S., Schioth H.B., Lehnert H., Schultes B., Born J., et al. Intranasal insulin enhances postprandial thermogenesis and lowers postprandial serum insulin levels in healthy men. Diabetes 2011, 60:114-118.
34. Krug R., Benedict C., Born J., Hallschmid M. Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory. J Clin Endocrinol Metab 2011, 95:E468-472.
35. Perras B., Wagner U., Born J., Fehm H.L. Improvement of sleep and pituitary-adrenal inhibition after subchronic intranasal vasopressin treatment in elderly humans. J Clin Psychopharmacol 2003, 23:35-44.
36. Born J., Lange T., Kern W., McGregor G.P., Bickel U., Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002, 5:514-516.
37. Watson C.J., Soto-Calderon H., Lydic R., Baghdoyan H.A. Pontine reticular formation (PnO) administration of hypocretin-1 increases PnO GABA levels and wakefulness. Sleep 2008, 31:453-464.
38. Montplaisir J., Billiard M., Takahashi S., Bell I.R., Guilleminault C., Dement W.C. Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption. Biol Psychiatry 1978, 13:73-89.
39. Weinhold S.L., Seeck-Hirschner M., Nowak A., Goder R., Baier P.C. Wake-REM sleep transitions for measuring REM sleep disturbance: Comparison between narcolepsy, idiopathic hypersomnia and healthy controls. Sleep Biol Rhythms 2011, 9:172-177.
40. Mattarozzi K., Bellucci C., Campi C., Cipolli C., Ferri R., Franceschini C., et al. Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy/cataplexy. Sleep Med 2008, 9:425-433.